NCT00345358View on ClinicalTrials.gov

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

September 18, 2006

Primary Completion Date

November 15, 2007

Study Completion Date

November 15, 2007

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Synflorix

1, 2, 3 or 4 Intramuscular injections, depending on age group

BIOLOGICAL

Infanrix IPV/Hib

4 intramuscular injections

Trial Locations (10)

15140

GSK Investigational Site, Lahti

33100

GSK Investigational Site, Tampere

48600

GSK Investigational Site, Kotka

60100

GSK Investigational Site, Seinäjoki

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00345358 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter